Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA 94080, USA.
Bioanalysis. 2022 May;14(9):603-613. doi: 10.4155/bio-2022-0035. Epub 2022 May 17.
Antisense oligonucleotides (ASOs) are a fast-growing drug modality. Pharmacokinetic characterization and accurate quantification of ASOs is critical for drug development. LC-MS and hybridization immunoassays are common methods to quantify ASOs but may lack sensitivity. In this study we aimed to develop an ASO quantification method with improved sensitivity. We developed a branched DNA approach for ASO quantification and compared it with hybridization immunoassays. The branched DNA assay showed significantly improved sensitivity, with LLOQ 31.25 pg/ml in plasma, 6.4-and 16-fold higher than dual-probe hybridization electrochemiluminescence and single-probe hybridization ELISA, respectively, with adequate precision, accuracy, selectivity and specificity and acceptable matrix interference. Branched DNA for ASO quantification has significantly higher sensitivity and lower hemolysis interference.
反义寡核苷酸(ASO)是一种快速发展的药物模式。药代动力学特征和 ASO 的准确定量对于药物开发至关重要。LC-MS 和杂交免疫分析是定量 ASO 的常用方法,但可能缺乏灵敏度。在这项研究中,我们旨在开发一种灵敏度更高的 ASO 定量方法。我们开发了一种用于 ASO 定量的分支 DNA 方法,并将其与杂交免疫分析进行了比较。分支 DNA 测定法显示出显著提高的灵敏度,LLOQ 在血浆中为 31.25 pg/ml,分别比双探针杂交电化学发光和单探针杂交 ELISA 高 6.4 倍和 16 倍,具有足够的精密度、准确性、选择性和特异性以及可接受的基质干扰。用于 ASO 定量的分支 DNA 具有更高的灵敏度和更低的溶血干扰。